Company description

Emergent BioSolutions, Inc. (ticker symbol EBS) is a global specialty biopharmaceutical company that develops and manufactures products to address public health threats. With headquarters in Gaithersburg, Maryland, Emergent BioSolutions has over two decades of experience in researching, developing, and producing vaccines and therapeutics for serious and emerging diseases. Their portfolio includes FDA-licensed products such as anthrax vaccine BioThrax® and smallpox vaccine ACAM2000®, as well as candidate treatments for diseases like Zika, Ebola, and COVID-19. Emergent BioSolutions is committed to protecting public health and improving global preparedness for potential health crises through their innovative and high-quality products. Additionally, the company has a diverse and talented workforce of over 1,600 employees worldwide, who are dedicated to delivering on their mission of developing and producing lifesaving medical solutions. Through strategic partnerships and collaborations, Emergent BioSolutions continues to expand its capabilities and pursue groundbreaking treatments for a wide range of diseases, making them a leader in the biopharmaceutical industry.